Insys Therapeutics (INSY) Misses Q2 EPS by 10c; DEA Quota Granted
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insys Therapeutics Reports Second Quarter 2015 Results
August 6, 2015 6:50 AM EDTPHOENIX, AZ -- (Marketwired) -- 08/06/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three- and six-month periods ended June 30, 2015. Highlights of and subsequent to the second quarter of 2015 include:
Total net revenue increased to $77.6 million versus $55.7 million for the second quarter of 2014; Revenues from Subsys (fentanyl sublingual spray) were $76.7 million, up 40% compared with second quarter 2014 sales of $54.6 million; Net income was $7.3 million, or $0.10 per basic and diluted share, compared to net income of $9.5 million, or $0.14 per basic and $0.13 per diluted share, for the... MoreNTRR: U.S. Cannabis Industry Maintains Unprecedented Pace of Growth
August 5, 2015 5:00 AM EDTTAMPA, Fla.--(BUSINESS WIRE)-- As Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air... More
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
August 4, 2015 8:01 AM EDTPHOENIX, AZ -- (Marketwired) -- 08/04/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) candidate for the treatment of infantile spasms (IS).
"We are pleased to have received orphan drug designation for CBD to treat infantile spasms, a catastrophic form of childhood epilepsy," said Michael L. Babich, President and Chief Executive Officer. "If successful, our CBD product could offer certain children the potential to attain seizure control and to potentially... More
